IPI-145 1201438-56-3

簡要描述：IPI-145 1201438-56-3
Duvelisib is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immuno

產品型號：abs810399
廠商性質：生產廠家
更新時間：2026-02-04
訪問量：1291

產品咨詢聯系我們

Product Category

生化試劑

其它生化試劑植物提取物碳水化合物生物緩沖劑熒光探針與染料表面活性劑酶&輔酶&酶底物蛋白質組學動植物激素小分子化合物生化檢測試劑盒逆行示蹤劑抗生素核苷&核苷酸多肽

品牌	absin	CAS	1201438-56-3
分子式	C22H17ClN6O	純度	＞98%
分子量	416.86	貨號	abs810399
規格	5mg	供貨周期	現貨
主要用途	is an orally bioavailable	應用領域	化工,生物產業,農林牧漁,制藥/生物制藥,綜合

IPI-145 1201438-56-3

產品描述
描述	Duvelisib is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.
純度	>98%
儲存/保存方法	Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
基本信息
別名	IPI-145; INK1197
外觀	白色至類白色粉末
可溶性/溶解性	DMSO : 77 mg/mL (184.7 mM)
生物活性
靶點	PI3Kα,PI3Kβ,PI3Kγ, PI3Kδ
In vitro(體外研究)	IPI-145 suppresses murine/human B-cell proliferation with EC50 of 0.5 nM/0.5 nM and also inhibits human T-cell proliferation with EC50 of 9.5 nM.
In vivo(體內研究)	IPI-145 (10 mg/kg, p.o.) shows well pharmacokinetics with Cmax and AUC of 390 ng/mL and 137 ng•h/mL in mouse and rat. IPI-145 (10 mg/kg) is active in murine DTH model with ~50% ear swelling. IPI-145 (10 mg/kg) demonstrates dose-dependent effect in rat collagen induced arthritis (CIA) model. IPI-145 prevents inflammation and protects joint bone and cartilage in the rat CIA model. IPI-145 (10 mg/kg,QD) demonstrates activity in rat adjuvant induced polyarthritis model.